

- SKBR-3 breast cancer cells. *Oncology Reports* 2005; 14: 489-494.
- 190) Sata R, Ohtani H, Tsujimoto M, Murakami H, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Nagata H, Tsukimori K, Nakano H, and Sawada Y. Functional analysis of organic cation transporter 3 expressed in human placenta. *J. Pharmacol. Expt. Therapeut.* 2005; 315:888-895.
- 191) Fukuda T, Ashizuka M, Nakamura T, Shibahara K, Maeda K, Izumi H, Kohno K, Kuwano M, and Uchiumi T. Characterization of 5'-untranslated region of YB-1 mRNA and autoregulation of translation by YB-1 protein. *Nucleic Acids Res.* 2004; 32: 611-622.
- 192) Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M, and Ono M. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. *FASEB J.* 2004; 18: 300-310.
- 193) Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, and Kuwano M. Sensitivity to gefitinib ('Iressa', ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. *Molec. Cancer Therapeut.* 2004; 3: 465-472.
- 194) Hisaeda K, Inokuchi A, Nakamura T, Kohno K, Iwamoto Y, Kuwano M, and Uchiumi, T. Interleukin-1 β represses *MRP2* gene expression through inactivation of interferon regulatory factor 3 in HepG2 cells. *Hepatology* 2004; 39: 1574-1582.
- 195) Hirata A, Uehara H, Izumi K, Naito S, Kuwano M, and Ono M. Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). *Cancer Sci.* 2004; 95: 614-618.
- 196) Hirata K, Masuda K, Morikawa W, He J-W, Kuraoka A, Kuwano M, and Kawabuchi M. N-myc downstream-regulated gene 1 expression in injured sciatic nerves. *GLIA*, 2004; 47: 325-334.
- 197) Kuwano M, Oda Y, Izumi H, Yang S-J, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, Kamura T, Tsuneyoshi M, Yasumoto K, and Kohno K. The role of nuclear YB-1 as a global marker in drug resistance. *Molec. Cancer Therapeut.* 2004; 3: 1458-1492.
- 198) Yoshioka S, Okawa C, Takahashi S, Katayama K, Tsukahara S, Mitsuhashi J, and Sugimoto Y. The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional protein. *Pharm. Res.* : *in press*.
- 199) Katayama K, Masuyama K, Yoshioka S, Hasegawa H, Mitsuhashi J, and Sugimoto Y. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. *Cancer Chemother. Pharmacol.* : *in press*.
- 200) Yanase K, Tsukahara S, Mitsuhashi J, and Sugimoto Y. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. *Cancer Letters* 2006; 234: 73-80.
- 201) Mutoh K, Mitsuhashi J, Kimura Y, Tsukahara S, Ishikawa E, Sai K, Ozawa S, Sawada J, Ueda K, Katayama K, and Sugimoto Y. A T3587G germ-line mutation of the *MDR1* gene encodes a nonfunctional P-glycoprotein. *Mol. Cancer Ther.* 2006; 5: 877-884.
- 202) Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, and Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in *MDR1*-transduced human breast cancer cells. *Cancer Sci.* 2006; 97: 1198-1204.
- 203) Imai Y, Ishikawa E, Asada S, and Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. *Cancer Res.* 2005; 65: 596-604.
- 204) Morita H, Koyama K, Sugimoto Y, and Kobayashi J. Antimitotic activity and reversal of breast cancer resistance protein-mediated drug resistance by stilbenoids from *Bletilla striata*. *Bioorg. Med. Chem. Lett.* 2005; 15: 1051-1054.
- 205) Sugimoto Y, Tsukahara S, Ishikawa E, and Mitsuhashi J. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. *Cancer Sci.* 2005; 96: 457-465.

- 206) Kage K, Fujita T, and Sugimoto Y. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. *Cancer Sci.* 2005; 96: 866-872.
- 207) Imai Y, Tsukahara S, Mitsunashi J, and Sugimoto Y. Functional single nucleotide polymorphisms of the ABC-transporter ABCG2/BCRP gene. *Trends in Cancer Res.* 2005; 1: 111-120.
- 208) Imai Y, Tsukahara S, Asada S, and Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. *Cancer Res.* 2004; 64: 4346-4352.
- 209) Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, and Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. *Mol. Cancer Ther.* 2004; 3: 1119-1125.
- 210) Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, Sugimoto Y, Akiyama S, and Baba M. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. *Biochem. Pharmacol.* 2004; 68: 1363-1370.
- 211) Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y, Maehara Y. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. *Breast Cancer Res Treat* 2007; 101(3): 249-57.
- 212) Yamanaka T, Okamoto T, Ichinose Y, Oda S, Maehara Y. Methodological aspects of current problems in target-based anticancer drug development. *Int J Clin Oncol* 2006; 11(3): 167-75.
- 213) Tokunaga E, Oki E, Nishida K, Koga T, Yoshida R, Ikeda K, Kojima A, Egashira A, Morita M, Kakeji Y, Maehara Y. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. *Breast Cancer Res Treat* 2006; 97(2): 199-203.
- 214) Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, Kakeji Y, Maehara Y. Trastuzumab and breast cancer: developments and current status. *Int J Clin Oncol* 2006; 11(3): 199-208.
- 215) Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H, Maehara Y. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. *Int J Cancer* 2006; 118(2): 284-9.
- 216) Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. *Breast Cancer* 2006; 13(2): 137-44.
- 217) Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, Ohno S, Maehara Y. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. *Eur J Cancer* 2006; 42(5): 629-35.
- 218) Takahashi I, Emi Y, Kakeji Y, Tokunaga E, Ushiro S, Oki E, Watanabe M, Baba H, Maehara Y. Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer. *Oncol Rep* 2006; 15(4): 849-54.
- 219) Oki E, Kakeji Y, Yoshida R, Ikeda K, Nishida K, Koga T, Egashira A, Tokunaga E, Morita M, Baba H, Maehara Y. [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC)]. *Gan To Kagaku Ryoho* 2006; 33 Suppl 1: 138-43.
- 220) Oki E, Kakeji Y, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Yamamoto M, Ikebe M, Maehara Y. Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. *J Gastroenterol Hepatol* 2006; 21(5): 814-8.
- 221) Mizokami K, Kakeji Y, Oda S, Maehara Y. Relationship of hypoxia-inducible factor 1alpha and p21^{WAF1/CIP1} expression to cell apoptosis and clinical outcome in patients with gastric cancer. *World J Surg Oncol* 2006; 4: 94.
- 222) Mizokami K, Kakeji Y, Oda S, Irie K, Yonemura T, Konishi F, Maehara Y.

- Clinicopathologic significance of hypoxia-inducible factor 1 α overexpression in gastric carcinomas. *J Surg Oncol* 2006; 94(2): 149-54.
- 223) Aishima S, Basaki Y, Oda Y, Kuroda Y, Nishihara Y, Taguchi K, Taketomi A, Maehara Y, Hosoi F, Maruyama Y, Fotovati A, Oie S, Ono M, Ueno T, Sata M, Yano H, Kojiro M, Kuwano M, and Tsuneyoshi M. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. *Cancer Sci.* 2006; 97: 1182-1190.
- 224) Yoshino I, Osoegawa A, Yohena T, Kameyama T, Oki E, Oda S, Maehara Y. Loss of heterozygosity (LOH) in non-small cell lung cancer: difference between adenocarcinoma and squamous cell carcinoma. *Respir Med* 2005; 99(3): 308-12.
- 225) Yamamoto M, Mashino K, Shibahara K, Oki E, Kakeji Y, Baba H, Maehara Y. [Evaluation of positive cases with peritoneal lavage cytology in gastric cancer]. *Gan To Kagaku Ryoho* 2005; 32(10): 1389-92.
- 226) Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E, Nakano H. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. *Clin Cancer Res* 2005; 11(13): 4783-92.
- 227) Oki E, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Watanabe M, Ikebe M, Kakeji Y, Baba H, Maehara Y. Genetic mutual relationship between PTEN and p53 in gastric cancer. *Cancer Lett* 2005; 227(1): 33-8.
- 228) Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. *Int J Cancer* 2005; 117(3): 376-80.
- 229) Oda S, Zhao Y, Maehara Y. Microsatellite instability in gastrointestinal tract cancers: a brief update. *Surg Today* 2005; 35(12): 1005-15.
- 230) Oda S, Maehara Y, Ikeda Y, Oki E, Egashira A, Okamura Y, Takahashi I, Kakeji Y, Sumiyoshi Y, Miyashita K, Yamada Y, Zhao Y, Hattori H, Taguchi K, Ikeuchi T, Tsuzuki T, Sekiguchi M, Karran P, Yoshida MA. Two modes of microsatellite instability in human cancer: differential connection of defective DNA mismatch repair to dinucleotide repeat instability. *Nucleic Acids Res* 2005; 33(5): 1628-36.
- 231) Kimura Y, Oda S, Egashira A, Kakeji Y, Baba H, Nakabeppu Y, Maehara Y. A variant form of hMTH1, a human homologue of the E coli mutT gene, correlates with somatic mutation in the p53 tumour suppressor gene in gastric cancer patients. *J Med Genet* 2004; 41(5): e57.
- 232) Araki K, Wang B, Miyashita K, Cui Q, Ohno S, Baba H, Zhang RG, Sugimachi K, Maehara Y, Oda S. Frequent loss of heterozygosity but rare microsatellite instability in oesophageal cancer in Japanese and Chinese patients. *Oncology* 2004; 67(2): 151-8.
- 233) Shibahara K, Uchiumi T, Fukuda T, Kura S, Tominaga Y, Maehara Y, Kohno K, Nakabeppu Y, Tsuzuki T, and Kuwano M. Targeted disruption of one allele of the Y-box binding-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C. *Cancer Sci.* 2004; 95: 348-353.
- 234) Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, and Matsumura Y. Novel SN-38- incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor- secreting bulky tumors. *Cancer Res.* 2006; 66: 10048-10056.
- 235) Negishi T, Koizumi F, Uchino H, Kuroda J, Kawaguchi T, Naito S, and Matsumura Y. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. *Br. J. Cancer* 2006; 95: 601-606.
- 236) Shimoyama T., Koizumi F, Fukumoto H, Kiura K, Tanimoto M, Saijo N, and Nishio K. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. *Lung Cancer* 2006; 53: 13-21.
- 237) Shimoyama T, Hamano T, Natsume T, Koizumi

- F, Kiura K, Tanimoto M, and Nishio K. Reference profiling of the genomic response induced by an anti-microtubule agent TZT-1027 (Soblidotin) *in vitro*. *Pharmacogenomics J*. 2006; 6: 388-396.
- 238) Arao T, Yanagihara K, Takigahira M, Takeda M, Koizumi F, Shiratori Y, and Nishio K. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. *Int. J. Cancer* 2006; 118: 483-489.
- 239) Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, Nishio K. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. *Int J Cancer* 2004; 108(3): 464-472.
- 240) Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. *Cancer Sci*. 2004; 95(12): 984-989.
- 241) Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, and Nishio M. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. *Chest* 2007; *in press*.
- 242) Wakasugi T, Izumi H, Uchiumi T, Suzuki H, Arao T, Nishio K, and Kohno K. ZNF143 interacts with p73 and is involved in cisplatin resistance. *Oncogene* 2006; *Epub ahead of print*.
- 243) Sone T, Kasahara K, Kimura H, Nishio K, Mizuguchi M, Nakatsumi Y, Shibata K, Waseda Y, Fujimura M, and Nakao S. Comparative analysis of epithelial growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with non-small-cell lung cancer. *Cancer* 2007; *in press*.
- 244) Sekine I, Nishio K, Tamura T, and Saijo N. A literature review of genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents. *Jpn J Clin Oncol*. 2007; *in press*.
- 245) Igarashi Y, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, Uramoto H, Sugio K, Yasumoto K, Sasaguri Y, Wang KY, Otuji Y, and Kohno K. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. *Oncogene* 2006; *Epub ahead of print*.
- 246) Ohashi R, Takahashi F, Cui R, Yoshioka M, Gu T, Sasaki S, Tominaga S, Nishio K, Tanabe K, and Takahashi K. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. *Cancer Lett*. 2006; *Epub ahead of print*.
- 247) Nishio K, and Arao T. Progress in the field of molecular biology and application of biotechnology to medical oncology. *Acta Med Kinki Univ*. 2006; 31: 57-62.
- 248) Kawaishi M, Yokote H, Kimura H, Kasahara K, and Nishio K. Development and characterization of an antibody specifically recognizing a mutant EGFR (L858R) protein expressed frequently in non-small cell lung cancer. *Acta Med Kinki Univ*. 2006; 31: 67-74.
- 249) Nishio M, Taguchi F, Ohyanagi F, Horiike A, Ishikawa Y, Satoh Y, Okumura S, Nakagawa K, and Nishio K. Gefitinib efficacy associated with multiple expression of HER family in non-small cell lung cancer. *Anticancer Res*. 2006; 26: 3761-3765.
- 250) Kato T, and Nishio K. Clinical aspects of epidermal growth factor receptor inhibitors: Benefit and risk. *Respirology* 2006; 11: 693-698.
- 251) Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S, Ono M, Izumi H, Kohno K, Sakai K, Shikmoyama T, Nishio K, and Kuwano M. Akt-dependent nuclear localization of malignant characteristics by ovarian cancer cells. *Oncogene* 2006; *Epub ahead of print*.
- 252) Nishio K, Arao T, Kato T, and Yokote H. EGFR mutation in various tissues. *Cancer Chemother Pharmacol*. 2006; 58: 39-41.
- 253) Yanagihara K, Takigahira M, Takeshita F, Komatsu T, Nishio K, Hasegawa F, and Ochiya T. A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. *Cancer Res*. 2006; 66: 7532-7539.
- 254) Kimura H, Kasahara K, Shibata K, Sone T,

- Yoshimoto A, Kita K, Ichikawa Y, Waseda Y, Watanabe K, Shirasaki H, Ishiura Y, Mizuguchi M, Nakatsumi Y, Kashii T, Kobayashi M, Kunitoh H, Tamura T, Nishio K, Fujimura M, and Nakao S. EGFR mutation of tumor and serum in the gefitinib treated patients with chemotherapy-naive non-small cell lung cancer. *Int Thoracic Oncol.* 2006; 1: 260-267.
- 255) Park S, Shimizu C, Shimoyama T, Takeda M, Kinoshita T, Kohno T, Katsumata N, Kang YK, and Nishio K, Fujiwara Y. Gene expression profiling of ATP binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. *Breast Cancer Res.* 2006; 99: 9-17.
- 256) Sekine I, Minna D, Nishio K, Tamura T, Saijo N. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. *J Thoracic Oncol.* 2006; 1: 31-37.
- 257) Yamanaka R, Arai T, Yajima N, Homma J, Genkai N, Sano M, Sekijima M, and Nishio K. Identification of expressed genes characterizing long-term survival in malignant glioma patients. *Oncogene* 2006; 25: 5994-6002.
- 258) Yamada Y, Yamamoto N, Shimoyama T, Horiike A, Fujisaka Y, Takayama K, Sakamoto T, Nishioka Y, Yasuda S, Tamura T. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. *Cancer Sci.* 2005; 96(10): 721-8.
- 259) Nishio K, Arai T, Shimojima T, Fujiwara Y, Tamura T, and Saijo N. Translational studies for target-based drugs. *Cancer Chemother Pharmacol* 2005; 56: s90-s93.
- 260) Ando K, Ohmori T, Inoue F, Kadofuku T, Hosaka T, Ishida H, Shirai T, Okuda K, Hirose T, Horichi N, Nishio K, Saijo N, Adachi M, and Kuroki T. Enhancement of sensitivity to tumor necrosis factor α in non-small cell lung cancer cells with acquired resistance to gefitinib. *Clin Cancer Res.* 2005; 11: 8872-8879.
- 261) Kimura H, Kasahara K, Sekijima M, Tamura T, and Nishio K. Plasma MIP- β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosin kinase inhibitor, gefitinib. *Lung Cancer* 2005; 50: 393-399.
- 262) Shimura M, Saito A, Matsuyama S, Sakuma T, Terui Y, Ueno K, Yumoto H, Yamauchi K, Yamamura K, Mimura H, Sano Y, Yabashi M, Tamasaku K, Nishio K, Nishino Y, Endo K, Hatake K, Mori Y, Ishizaka Y, and Ishikawa T. Element array by scanning X-ray fluorescence microscopy after cis-deaminedichloro-platinum (II) treatment. *Cancer Res.* 2550; 65: 4998-5002.
- 263) Yanagihara K, Takigahira M, Tanaka H, Komatsu T, Fukumoto H, Koizumi F, Nishio K, Ochiya T, Ino Y, and Hirohashi S. Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. *Cancer Sci.* 2005; 96: 323-332.
- 264) Nishio M, Ohyanagi F, Horiike A, Ishikawa Y, Satoh Y, Okumura S, Nakagawa K, Nishio K, and Horai T. Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. *Br. J. Cancer* 2005; 92: 1877-1880.
- 265) Koizumi F, Shimoyama T, Taguchi F, Saijo N, and Nishio K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. *Int. J. Cancer* 2005; 116: 36-44.
- 266) Park JK, Lee SH, Kang JH, Nishio K, Saijo N, and Kuh HJ. Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells. *Anticancer Drugs* 2004; 15: 809-818.
- 267) Koizumi F, Kanzawa F, Ued Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, and Nishio K. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ('Iressa') and the DNA topoisomerase I inhibitor CPT-11 (Irinotecan) in human colorectal cancer cells. *Int. J. Cancer* 2004; 108: 464-472.
- H. 知的財産権の出願・登録状況 (予定を含む。)
1. 特許取得
- 特願 2006-213334
骨転移抑制剤
 - 特願 2003-332584
MDRI 遺伝子の 5' 制御領域における SNPs

[出願中]

- 悪性神経膠腫患者の予後を規定する遺伝子同定
 - ゲフィチニブの効果予測因子（プロテオミクス）
 - 血清中EGFR遺伝子変異の高感度検出法
 - チロシンキナーゼ阻害剤に対する感受性予測因子としてのHLAサブタイプ測定
 - 悪性神経膠腫に高発現する遺伝子の同定
 - EGFR遺伝子変異特異的抗体の開発
 - 胃癌高発現遺伝子特定による胃癌診断および創薬への利用（特願2006-306057）
 - ZNF143遺伝子
2. 実用新案登録
なし
 3. その他
なし

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
<u>Kuwano M</u> , Basaki Y, Kuwano T, Nakao S, Oie S, Kimura Y N, Fujii T, and Ono M.	The critical role of inflammatory cell infiltration in tumor angiogenesis-a target for anti-tumor drug development?	Roberta V. Zubar	New Angiogenesis Research	Nova Science Publishers Inc.	New York	2005	157-170
内海健、和田守正、桑野信彦	VI-2.抗がん剤感受性とDubin-Johnson 症候群	植田和光	ABC 蛋白質	学会出版センター	東京都	2005	135-157
桑野信彦、小野真弓	がん治療の最前線と今後の展望	金倉謙	臨床腫瘍内学入門	永井書店	大阪府	2005	71-74
桑野信彦、細井文仁、大家真治、小野真弓	6.分子標的治療	門田守人 松浦成昭	癌転移のメカニズムがよくわかる 肝転移のすべて	永井書店	大阪府	2005	118-124
三島麻衣、丸山祐一郎、桑野隆史、 <u>桑野信彦</u>	消化器がんの分子標的治療	市倉 隆	消化器がん化学療法 2004	日本対がん学会 センター	東京都	2004	59-72

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Saijo N.</u>	Recent trends in the treatment of advanced lung cancer.	Cancer Sci.	97(6)	448-452	2006
Saijo T, Ishii G, Ochiai A, Yoh K, Goto K, Nagai K, Kato H, Nishiwaki Y, <u>Saijo N.</u>	Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimetabolic agents combined with platinum chemotherapy.	Lung Cancer	54(2)	217-25	2006
Wislez M, Beer DG, Wistuba I, Cadranel J, <u>Saijo N</u> , Johnson BE.	Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma.	J Thoracic Oncol.	1(9)	S8-S12	2006

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, <u>Saijo N</u> , <u>Tamura T</u> .	Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer.	Lung cancer	53(2)	157-164	2006
Koizumi F, Shimoyama T, Taguchi F, <u>Saijo N</u> , and <u>Nishio K</u> .	Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.	Int. J. Cancer	116	36-44	2005
Taguchi F, Kusaba H, Asai A, Iwamoto Y, Yano K, Nakano H, Mizukami T, <u>Saijo N</u> , Kato H, and <u>Nishio K</u> .	hnRNP L enhances sensitivity of the cells to KW-2189.	Int. J. Cancer	108	679-685	2004
Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, Takada M, Fukuoka M, and <u>Nakagawa K</u> .	Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells Bearing <i>EGFR</i> Gene Mutation and Amplification.	Cancer Res	67	2046-53	2007
Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, <u>Nakagawa K</u> , Takada M, Negoro S, Tamura K, Ando M, Tada T, and Fukuoka M.	Phase II Study of Etoposide and Cisplatin With Concurrent Twice-Daily Thoracic Radiotherapy Followed by Irinotecan and Cisplatin in Patients With Limited-Disease Small-Cell Lung Cancer: West Japan Thoracic Oncology Group 9902.	J Clin Oncol	24	5247-5252	2006
Kurata T, Tamura K, Okamoto I, Satoh T, <u>Nakagawa K</u> , and Fukuoka M.	Pemetrexed-induced edema of the eyelid.	Lung Cancer	54	241-242	2006
Saito H, Kudoh S, <u>Nakagawa K</u> , Negoro S, Matsui K, Semba H, and Takada M.	Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced non small-cell lung cancer.	Am J Clin Oncol	29	503-507	2006
Kurata T, Matsuo K, Takada M, Kawahara M, Tsuji M, Matsubara Y, Otani N, Matsuyama S, Muraishi K, Fujita T, Ishikawa M, Koyano K., Okamoto I, Satoh T, Tamura K, <u>Nakagawa K</u> , and Fukuoka M.	Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?	J Thorac Oncol	1	684-691	2006

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamamoto N, Nishimura Y, <u>Nakagawa K</u> , Matsui K, and Fukuoka M.	Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.	Cancer Chemother Pharmacol	58	285-291	2006
Kudoh S, Takeda K, <u>Nakagawa K</u> , Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, and Fukuoka M.	Phase III study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).	J Clin Oncol	24	3657-63	2006
Yamamoto N, <u>Nakagawa K</u> , Uejima H, Sugiura T, Takada Y, Negoro S, Matsui K, Kashii T, Takada M, Nakanishi Y, Kato T, and Fukuoka M.	Randomized Phase II study of Carboplatin/Gemcitabine versus Vinorelbine/Gemcitabine in Patients With Advanced Nonsmall Cell Lung Cancer. West Japan Thoracic Oncology Group(WJTOG) 0104.	Cancer	107	599-605	2006
Hyodo I, Shirao K, Doi T, Hatake K, Arai Y, Yamaguchi K, Tamura T, Takemiya S, Takiuchi H, <u>Nakagawa K</u> , and Mishima H.	A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.	Jpn J Clin Oncol	36	410-417	2006
Kaneda H, Kurata T, Tamura K, Uejima H, <u>Nakagawa K</u> , and Fukuoka M.	A Phase I Study of Irinotecan in Combination with Amrubicin for Advanced Lung Cancer Patients.	Anticancer Res	26	2479-85	2006
Asai G, Yamamoto N, Kurata T, Tamura K, Uejima H, <u>Nakagawa K</u> , and Fukuoka M.	Phase I and Pharmacokinetic Study of Combination Chemotherapy Using Irinotecan and Paclitaxel in Patients with Lung Cancer.	J Thorac Oncol	1	226-230	2006
<u>Nakagawa K</u> , Kudoh S, Matsui K, Negoro S, Yamamoto N, Latz J E, Adachi S, and Fukuoka M.	A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.	Br J Cancer	95	677-682	2006
<u>Nakagawa K</u> .	Clinical development of EGFR-tyrosine kinase inhibitors in Japan.	Cancer Chemother Pharmacol	58	33-37	2006
Okamoto I, Araki J, Suto R, Shimada M, <u>Nakagawa K</u> , and Fukuoka M.	EGFR mutation in gefitinib-responsive small-cell lung cancer.	Ann Oncol	17	1028-29	2006

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, <u>Nakagawa K</u> , Kudoh S, Takada M, Minato Y, and Fukuoka M.	Phase II study of weekly paclitaxel for Relapsed and refractory small cell lung cancer.	Anticancer Res	26	777-782	2006
Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K, Matsui K, Negoro S, <u>Nakagawa K</u> , and Fukuoka M.	EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.	Lung Cancer	51	363-68	2006
Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, and <u>Nakagawa K</u> .	Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.	Int J Cancer	118	812-20	2006
Matsui K, Hirashima T, Nitta T, Kobayashi M, Ogata Y, Furukawa M, Kudoh S, Yoshimura N, Mukohara T, Yamauchi S, Shiraishi S, Kamo H, Negoro S, Takeda K, <u>Nakagawa K</u> , Takada M, Yana T, and Fukuoka M.	A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.	Jpn J Clin Oncol	35	181-87	2005
Ohe Y, Negoro S, Matsui K, <u>Nakagawa K</u> , Sugiura T, Takada Y, Nishiwaki Y, Yokota S, Kawahara M, <u>Saijo N</u> , Fukuoka M, and Ariyoshi Y.	Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer.	Ann Oncol	16	430-36	2005
Kakiuchi S, Daigo Y, Ishikawa N, Furukawa C, Tsunoda T, Yano S, <u>Nakagawa K</u> , Tsuruo T, Kohno N, Fukuoka M, Sone S, and Nakamura Y.	Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).	Hum Mol Genet	13	3029-43	2004
Kaneda H, Tamura K, Kurata T, Uejima H, <u>Nakagawa K</u> , and Fukuoka M.	Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.	Lung Cancer	46	247-54	2004
Kurata T, Tamura K, Yamamoto N, Nogami T, Satoh T, Kaneda H, <u>Nakagawa K</u> , and Fukuoka M.	Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer.	Br J Cancer	90	2092-96	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kurata T, Tamura K, Kaneda H, Nogami T, Uejima H, Asai G, <u>Nakagawa K</u> , and Fukuoka M.	Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.	Ann Oncol	15	173-74	2004
Yamamoto N, Fukuoka M, Negoro S, <u>Nakagawa K</u> , Saito H, Matsui K, Kawahara M, Senba H, Takada Y, Kudoh S, Nakano T, Katakami N, Sugiura T, Hosoi T, and Ariyoshi Y. for the West Japan Thoracic Oncology Group.	Randomized phase II study of docetaxel/ cisplatin versus docetaxel/ irinotecan in advanced non-small cell lung cancer: a West Japan Thoracic Oncology Study (WJTOG9803).	Br J Cancer	90	87-92	2004
Ohe Y, Ohashi Y, Kubota K, <u>Tamura T</u> , <u>Nakagawa K</u> , Negoro S, Nishiwaki Y, <u>Saijo N</u> , Ariyoshi Y, Fukuoka M, for the FACS cooperative group.	Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.	Ann Oncol.	18	317-323	2007
Edelman MJ, Sekine I, <u>Tamura T</u> , and <u>Saijo N</u> .	Geographic variation in the second-line treatment of non-small cell lung cancer.	Semin Oncol.	33 (1 Suppl 1)	S39-44	2006
Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y, <u>Tamura T</u> .	Phase 1 Clinical Study of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Solid Tumors.	Jpn J Clin Oncol.	36(12)	768-74	2006
<u>Tamura T</u> , <u>Minami H</u> , Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, Kawada K, Ebi H, Sasaki Y, Jiang H, <u>Saijo N</u> .	A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.	J Thorac Oncol.	1(9)	1002-1009	2006
Kimura H, Fujiwara Y, Sone T, Kunitoh H, <u>Tamura T</u> , Kasahara K, <u>Nishio K</u> .	<i>EGFR</i> mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.	Br J Cancer	95	1390-1395	2006
Sekine I, Takada M, Nokihara H, Yamamoto S, <u>Tamura T</u> .	Knowledge of efficacy of treatments in lung cancer is not enough, their clinical effectiveness should also be known.	J Thorac Oncol.	1	398-402	2006

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kimura H, Fujiwara Y, Sone T, Kunitoh H, <u>Tamura T</u> , Kasahara K, <u>Nishio K</u> .	High sensitivity detection of <i>epidermal growth factor receptor</i> mutations in the pleural effusion of non-small cell lung cancer patients.	Cancer Sci.	97(7)	642-8	2006
Kimura H, Kasahara K, Kawaishi M, Kunitoh H, <u>Tamura T</u> , Holloway B, <u>Nishio K</u> .	Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.	Clin Cancer Res.	12(13)	3915-21	2006
Yamada Y, <u>Tamura T</u> , Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y.	Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.	Cancer Chemother Pharmacol.	58(2)	173-82	2006
Sakai K, Yokote H, Murakami-Murofushi K, <u>Tamura T</u> , <u>Saijo N</u> , <u>Nishio K</u> .	In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.	Biochem J.	397(3)	537-43	2006
Sakai K, Arao T, Shimoyama T, Murofushi K, Sekijima M, Kaji N, <u>Tamura T</u> , <u>Saijo N</u> , <u>Nishio K</u> .	Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.	FASEB J.	20(2)	311-3	2006
Kimura H, Kasahara K, Shibata K, Sone T, Yoshimoto A, Kita K, Ichikawa Y, Waseda Y, Watanabe K, Shirasaki H, Ishiura Y, Mizuguchi M, Nakatsumi Y, Kashii T, Kobayashi M, Kunitoh H, <u>Tamura T</u> , <u>Nishio K</u> , Fujimura M, and Nakao S.	EGFR mutation of tumor and serum in the gefitinib treated patients with chemotherapy-naïve non-small cell lung cancer.	Int Thoracic Oncol.	1	260-267	2006
Yamada Y, Yamamoto N, Shimoyama T, Horiike A, Fujisaka Y, Takayama K, Sakamoto T, Nishioka Y, Yasuda S, <u>Tamura T</u> .	Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.	Cancer Sci.	96(10)	721-8	2005
Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, Ohe Y, <u>Tamura T</u> , Kodama T, Asamura H, Tsuchiya R, <u>Saijo N</u> .	Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.	Lung Cancer.	49(2)	217-23	2005

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, <u>Tamura T.</u>	Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non-Small-Cell Lung Cancer.	J. Clin. Oncol.	23(28)	6829-37	2005
Sekine I, <u>Tamura T.</u>	Phase 1 clinical trials in oncology.	N. Engl. J. Med.	352(23)	2451-3	2005
Yamamoto N, <u>Tamura T.</u> , Murakami H, Shimoyama T, Nokihara H, Ueda Y, Sekine I, Kunitoh H, Ohe Y, Kodama T, Shimizu M, <u>Nishio K.</u> , Ishizuka N, <u>Saijo N.</u>	Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.	J. Clin. Oncol.	23(6)	1061-9	2005
Kimura H, Kasahara K, Sekijima M, <u>Tamura T.</u> and <u>Nishio K.</u>	Plasma MIP- β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosin kinase inhibitor, gefitinib.	Lung Cancer	50	393-399	2005
Arao T, Fukumoto H, Takeda M, <u>Tamura T.</u> , <u>Saijo N.</u> , <u>Nishio K.</u>	Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.	Cancer Res.	64(24)	9101-9104	2004
Taguchi F, Koh Y, Koizumi F, <u>Tamura T.</u> , <u>Saijo N.</u> , <u>Nishio K.</u>	Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.	Cancer Sci.	95(12)	984-989	2004
Goto K, Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Niho S, Kodama T, Shinkai T, <u>Tamura T.</u> , Ohe Y, Kunitoh H, Yamamoto N, Nokihara H, Yoshida K, Sugiura T, Matsui K, <u>Saijo N.</u>	Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.	Br. J. Cancer	91(4)	659-665	2004
Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, <u>Tamura T.</u> , Kodama T, Sumi M, <u>Saijo N.</u>	Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.	Cancer Sci.	95(8)	691-695	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N.	Risk factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.	Lung Cancer	45(1)	93-104	2004
Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N.	Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials.	Cancer Treat. Rev.	30(4)	359-368	2004
Koizumi F, Kanzawa F, Ued Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, and Nishio K.	Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ('Iressa') and the DNA topoisomerase I inhibitor CPT-11 (Irinotecan) in human colorectal cancer cells.	Int. J. Cancer	108	464-472	2004
Taguchi H, Ohkubo A, Sekine M, Seio K, Kakeya H, Osada H, Sasaki T.	Synthesis and biological properties of new phosmidosine analogs having an N-acylsulfamate linkage.	Nucleos. Nucleot. Nucl.	25	647-654	2006
Nagumo Y, Kakeya H, Shoji M, Hayashi Y, Dohmae N, Osada H.	Epolactaene binds human Hsp60 Cys442 resulting in the inhibition of chaperone activity	Biochem. J.	387	835-840	2005
Mitsui T, Miyake Y, Kakeya H, Osada H, Kataoka T.	Epoxycyclohexenone, a specific inhibitor of Fas ligand-dependent apoptosis in CTL-mediated cytotoxicity.	J. Immunology	172	3428-3436	2004
Sekine M, Okada K, Seio K, Kakeya H, Osada H.	Structure-activity relationship of phosmidosine: importance of the 7,8-dihydro-8-oxoadenosine residue for antitumor activity	Bioorg. Med. Chem.	12	5193-5201	2004
Sekine M, Okada K, Seio K, Obata T, Sasaki T, Kakeya H, Osada H.	Synthesis of a biotin-conjugate of phosmidosine O-ethyl ester as a G1 arrest antitumor drug.	Bioorg. Med. Chem.	12	6343-6349	2004
Nagumo Y, Kakeya H, Yamaguchi J, Uno T, Shoji M, Hayashi Y, Osada H.	Structure-activity relationships of epolactaene derivatives: Structural requirements for inhibition of Hsp60 chaperone activity.	Bioorg. Med. Chem. Lett.	14	4425-4429	2004
Watanabe N, Nishihara Y, Yamaguchi T, Koito A, Miyoshi H, Kakeya H, Osada H.	Fumagillin suppresses HIV-1 infection of macrophages through the inhibition of VPR activity.	FEBS Lett.	580	2598-2602	2006

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsuzawa M, <u>Kakeya H</u> , Yamaguchi J, Shoji M, Onose R, Osada H, Hayashi Y.	Enantio- and diastereoselective total synthesis of (+)-panepophenanthrin, an ubiquitin-activating enzyme inhibitor, and biological properties of its new derivatives.	Chem. Asian. J.	1	845-851	2006
Shiina I, Uchimaru T, Shoji M, <u>Kakeya H</u> , Osada H, Hayashi Y.	Computational study on the reaction mechanism of the key thermal [4+4] cycloaddition reaction in the biosynthesis of epoxytwinol A.	Org. Lett.	8	1041-1044	2006
Yamaguchi J, Toyoshima M, Shoji M, <u>Kakeya H</u> , Osada H, Hayashi Y.	Concise, enantio- and diastereo-selective total syntheses of fumagillol, RK-805, FR65814, ovalicin and 5-demethylovalicin, using the proline-mediated, catalytic, asymmetric α -aminooxylation.	Angew. Chem. Int. Ed.	45	789-793	2006
Ueda S, Basaki Y, Yoshie M, Ogawa K, Sakisaka S, <u>Kuwano M</u> , and Ono M.	PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib.	Cancer Res.	66	5346-5353	2006
Fotovati A, Fujii T, Yamaguchi M, Kage M, Shirouzu K, Oie S, Basaki Y, Ono M, Yamana H, and <u>Kuwano M</u> .	17 β -Estradiol induces downregulation of <i>Cap43/NDRG1/Drg-1</i> , a putative differentiation-related and metastasis suppressor gene, in human breast cancer cells.	Clin Cancer Res.	12	3010-3018	2006
Maruyama Y, Ono M, Kawahara A, Yokoyama T, Basaki Y, Kage M, Aoyagi S, Kinoshita H, and <u>Kuwano M</u> .	Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene <i>Cap43/NDRG1/Drg-1</i> through modulation of angiogenesis.	Cancer Res.	66	6233-6242	2006
Oie S, Ono M, Yano H, Maruyama Y, Terada T, Yamada Y, Ueno T, Kojiro M, Hirano K, and <u>Kuwano M</u> .	The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon- α .	Int. J. Oncol.	29	1469-1478	2006

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ono M, and <u>Kuwano M.</u>	Molecular mechanisms of epidermal growth factor receptor EGFR activation and responses to gefitinib and other EGFR-targeting drugs (CCR Forum).	Clin Cancer Res.	12	7242-7251	2006
Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, <u>Kuwano M.</u> and Kojiro M.	Growth inhibitory effects of regulated IFN α -2b on human liver cancer cells <i>in vitro</i> and <i>in vivo</i> .	Liver Int.	26	964-975	2006
Uchiumi T, Fotovati A, Sasaguri T, Shibahara K, Shimada T, Fukuda T, Nakamura T, Izumi H, Tsuzuki T, <u>Kuwano M.</u> and Kohno K.	YB-1 is important for an early stage embryonic development: Neural tube formation and cell proliferation.	J. Biol. Chem.	281	40440-40449	2006
Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, Momii Y, <u>Kuwano M.</u> and Kohno K.	Cisplatin resistance and transcription factors.	Curr. Med. Chem. -Anti-Cancer Agents	5	15-27	2005
Yokoyama G, Fujii T, Tayama K, Yamana H, <u>Kuwano M.</u> and Shirouzu K.	PKC δ and MAPK mediate G ₁ arrest induced by PMA in SKBR-3 breast cancer cells.	Biochem. Biophys. Res. Commun.	327	720-726	2005
Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, Yamamoto H, Yokoyama R, Uchiumi T, Iwamoto Y, <u>Kuwano M.</u> and Tsuneyoshi M.	ATP-binding cassette superfamily transporter gene expression in humansoft tissue sarcomas.	Int. J. Cancer	114	854-862	2005
Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, <u>Kuwano M.</u> and Ono M.	HER2 Overexpression Increases Sensitivity to Gefitinib, an EGF receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.	Cancer Res.	65	4253-4260	2005
Sanda T, Kuwano T, Nakao S, Iida S, Ishida T, Komatsu H, Shudo K, <u>Kuwano M.</u> Ono M, and Ueda R.	Antimyeloma effects of A novel synthetic retinoidAm80 (Tamibarotene) through inhibition of angiogenesis.	Leukemia	19	901-909	2005

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nakamura H, Takamori S, Fujii T, Ono M, Yamana H, <u>Kuwano M</u> , and Shirouzu K.	Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.	Cancer Lett.	230	33-46	2005
Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Hamano S, Sonoda K, Saijo Y, Nukiwa T, Ishibashi T, <u>Kuwano M</u> , and Ono M.	Infiltration of COX2-expressing macrophage is a prerequisite for IL-1beta-induced neovascularization and tumor growth.	J. Clinic. Invest.	115	2979-2991	2005
Fujii T, Nakamura A M, Yokoyama G, Yamaguchi M, Tayama K, Miwa K, Toh U, Kawamura D, Shirouzu K, Yamana H, <u>Kuwano M</u> , and Tsuda H.	Antineoplaston induces G ₁ arrest by PKC α and MAPK pathway in SKBR-3 Breast cancer cells.	Oncology Rep	14	489-494	2005
Sata R, Ohtani H, Tsujimoto M, Murakami H, Koyabu N, Nakamura T, Uchiumi T, <u>Kuwano M</u> , Nagata H, Tsukimori K, Nakano H, and Sawada Y.	Functional analysis of organic cation transporter 3 expressed in human placenta.	J. Pharmacol. Expt. Therapeut.	315	888-895	2005
桑野信彦、藤井輝彦	がん分子標的治療開発に関する基盤研究—ベッドサイドへの貢献を目指して	久留米医学会雑誌	68(1・2) 別冊	16-21	2005
桑野信彦	癌の分子標的治療の進歩	癌治療と宿主	17(3)	5	2005
桑野信彦	“イレッサ (ゲフィチニブ)”と“サリドマイド”と基礎医学への期待	臨床と研究	82(10)	19-20	2005
桑野信彦、小野眞弓	血管新生阻害剤	医学のあゆみ	215 (7)	607-612	2005
Fukuda T, Ashizuka M, Nakamura T, Shibahara K, Maeda K, Izumi H, Kohno K, <u>Kuwano M</u> , and Uchiumi T.	Characterization of 5'-untranslated region of YB-1 mRNA and autoregulation of translation by YB-1 protein.	Nucleic Acids Res.	32	611-622	2004
Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, <u>Kuwano M</u> , and Ono M.	Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis.	FASEB J.	18	300-310	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ono M., Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, and <u>Kuwano M.</u>	Sensitivity to gefitinib ('Iressa', ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.	Molec. Cancer Therapeut.	3	465-472	2004
Shibahara K, Uchiumi T, Fukuda T, Kura S, Tominaga Y, Maehara Y, Kohno K, Nakabeppu Y, Tsuzuki T, and Kuwano, M.	Targeted disruption of one allele of the Y-box binding-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C.	Cancer Sci.	95	348-353	2004
Hisaeda K, Inokuchi A, Nakamura T, Kohno K, Iwamoto Y, <u>Kuwano M.</u> and Uchiumi T.	IL-1 β represses multidrug resistance protein2 gene expression through inactivation of IRF3 in human hepatic cells.	Hepatology	39	1574-1582	2004
Hirata A, Uehara H, Izumi K, Naito S, <u>Kuwano M.</u> and Ono M.	Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839).	Cancer Sci.	95	614-618	2004
Hirata K, Masuda K, Morikawa W, He J-W, Kuraoka A, <u>Kuwano M.</u> and Kawabuchi M.	N-myc downstream-regulated gene 1 expression in injured sciatic nerves.	GLIA	47	325-334	2004
<u>Kuwano M.</u> , Oda Y, Izumi H, Yang S-J, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, Kamura T, Tsuneyoshi M, Yasumoto K, and Kohno K.	The role of nuclear YB-1 as a global marker in drug resistance.	Molec. Cancer Therapeut.	3	1458-1492	2004
桑野信彦、和田守正、和泉弘人、河野公俊	7.多剤耐性トランスポーター：抗がん剤のMDR 臨床薬理	臨床薬理	35(2)	89-96	2004
藤井輝彦、山名秀明、 <u>桑野信彦</u>	8. その他の治療 (1)血管新生阻害薬	胃癌治療 2004 臨床消化器内科	19(7)	980-987	2004
桑野信彦、藤井輝彦、小野真弓、河野公俊	序文：分子標的治療の現状と将来への展望	日本臨牀	62(7)	1211-1215	2004
河野公俊、和泉弘人、吉田毅、五十嵐友紀、若杉哲郎、新名一郎、初井泰朋、今泉拓也、 <u>桑野信彦</u>	4. 抗癌剤の感受性を担う分子標的とオーダーメイド化学療法	実験医学 増刊	22 (14)	180(2078)- 186(2084)	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yanase K, Tsukahara S, Mitsuhashi J, and <u>Sugimoto Y.</u>	Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.	Cancer Letters	234	73-80	2006
Mutoh K, Mitsuhashi J, Kimura Y, Tsukahara S, Ishikawa E, Sai K, Ozawa S, Sawada J, Ueda K, Katayama K, and <u>Sugimoto Y.</u>	A T3587G germ-line mutation of the MDR1 gene encodes a nonfunctional P-glycoprotein.	Mol. Cancer Ther.	5	877-884	2006
Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, and <u>Sugimoto Y.</u>	Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in <i>MDR1</i> -transduced human breast cancer cells.	Cancer Sci.	97	1198-1204	2006
Imai Y, Ishikawa E, Asada S, and <u>Sugimoto Y</u>	Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.	Cancer Res.	65	596-604	2005
Morita H, Koyama K, <u>Sugimoto Y.</u> and Kobayashi J	Antimitotic activity and reversal of breast cancer resistance protein-mediated drug resistance by stilbenoids from <i>Bletilla striata</i> .	Bioorg. Med. Chem. Lett.	15	1051-1054	2005
<u>Sugimoto Y.</u> , Tsukahara S, Ishikawa E, and Mitsuhashi J	Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/ pharmacodynamics.	Cancer Sci.	96	457-465	2005
Kage K, Fujita T, and <u>Sugimoto Y</u>	Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.	Cancer Sci.	96	866-872	2005
Imai Y, Tsukahara S, Asada S, and <u>Sugimoto Y</u>	Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.	Cancer Res.	64	4346-4352	2004
Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, and <u>Sugimoto Y.</u>	Gefitinib reverses breast cancer resistance protein-mediated drug resistance.	Mol. Cancer Ther.	3	1119-1125	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, <u>Sugimoto Y</u> , Akiyama S, and Baba M.	Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.	Biochem. Pharmacol.	68	1363-1370	2004
Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y, <u>Maehara Y</u> .	Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.	Breast Cancer Res Treat	101(3)	249-57	2007
Yamanaka T, Okamoto T, Ichinose Y, Oda S, <u>Maehara Y</u> .	Methodological aspects of current problems in target-based anticancer drug development.	Int J Clin Oncol	11(3)	167-75	2006
Tokunaga E, Oki E, Nishida K, Koga T, Yoshida R, Ikeda K, Kojima A, Egashira A, Morita M, Kakeji Y, <u>Maehara Y</u> .	Aberrant hypermethylation of the promoter region of the <i>CHFR</i> gene is rare in primary breast cancer.	Breast Cancer Res Treat	97(2)	199-203	2006
Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, Kakeji Y, <u>Maehara Y</u> .	Trastuzumab and breast cancer: developments and current status.	Int J Clin Oncol	11(3)	199-208	2006
Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H, <u>Maehara Y</u> .	Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients.	Int J Cancer	118(2)	284-9	2006
Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, <u>Maehara Y</u> .	Activation of PI3K/Akt signaling and hormone resistance in breast cancer.	Breast Cancer	13(2)	137-44	2006
Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, Ohno S, <u>Maehara Y</u> .	The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.	Eur J Cancer	42(5)	629-35	2006
Takahashi I, Emi Y, Kakeji Y, Tokunaga E, Ushiro S, Oki E, Watanabe M, Baba H, <u>Maehara Y</u> .	Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.	Oncol Rep	15(4)	849-54	2006